Overview

This trial is active, not recruiting.

Condition peripheral arterial disease
Treatments granulocyte-macrophage colony stimulating factor, placebo
Phase phase 2
Sponsor Emory University
Collaborator National Institutes of Health (NIH)
Start date September 2009
End date January 2013
Trial size 180 participants
Trial identifier NCT01041417, IRB00021976, NIH 1RC2HL101515-01

Summary

Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms and signs of peripheral arterial disease over placebo after four weeks of therapy. As well this study will examine whether improvements in blood vessel function can be observed. Finally, we will measure blood vessel function and stem cell levels in order to determine whether they can help to predict whether patients wither peripheral arterial disease will suffer further cardiovascular complications.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
Arm
(Experimental)
granulocyte-macrophage colony stimulating factor GM-CSF, Leukine
80 subjects will be randomized to receive GM-CSF Monday, Wednesday and Friday for 4 weeks of therapy.
(Placebo Comparator)
80 patients will receive placebo on Monday, Wednesday, and Friday for 4 weeks.
placebo
80 subjects will be randomized to receive placebo on Monday, Wednesday and Friday for 4 weeks.

Primary Outcomes

Measure
To investigate whether GM-CSF will improve symptoms of claudication in patients with PAD, measured objectively as improvement in treadmill exercise tolerance.
time frame: 6 months

Secondary Outcomes

Measure
Change in exercise tolerance will be due to improvement in collateral blood flow measured by ankle-brachial index, transcutaneous oxygen concentration, and calf blood flow measured by MRI, and/or improvement in endothelial dysfunction.
time frame: 6 months

Eligibility Criteria

Male or female participants from 21 years up to 80 years old.

Inclusion Criteria: - 160 males or post-menopausal females between 21 and 80 years of age. Female subjects must be (a) post-menopausal, (b) surgically sterile or (c) use adequate birth control and have a negative pregnancy test within 3 days prior to administration of study drug and should not be breastfeeding. - Documented PAD (By Ankle-Brachial Indices or Angiographically) - Clinically stable (at least 2 months) history of intermittent claudication with no change in symptom severity in the 2 months prior to screening. - On stable statin therapy for previous 3 months. - Peak Walking Time (PWT) between 1 and 12 minutes on a standardized Gardner treadmill protocol. - A Doppler-derived ankle-brachial index (ABI) of < 0.85 in the symptomatic limb after 10 minutes of rest at screening. For subjects with an ABI of >1.3 (non-compressible arteries) a Toe-Brachial Index (TBI) of < 0.70 must be obtained for subject qualification, or if ABI is > 0.85 to 1.0 , and a reduction of 20% in ABI measured within 1 minute of treadmill testing. - On appropriate and stable medical therapy for atherosclerosis for at least 2 months. - Able to give informed consent. - Diabetics with a dilated eye exam excluding proliferative retinopathy in the previous 12 months. Exclusion Criteria: - Recent or current active infections (treated with antibiotics). - Recent (3 months) change in statin therapy - Critical limb ischemia either chronic (category 3 and 4 of SVS classification) or acute ischemia manifested by rest pain, ulceration, or gangrene. - Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment. - Participation in a structured exercise treatment protocol within 3 months of enrollment. - Prior myeloid cancer. - Unstable angina, myocardial infarction, TIA, stroke or revascularization in the preceding 4 months. - Severe heart failure (Class III or IV), heart muscle disease or atrial fibrillation. - Limitation on exercise for symptoms other than intermittent claudication such as arthritis or dyspnea. - Uncontrolled diabetes mellitus (defined as HbA1c > 10.0). - Chronic renal disease (creatinine of >2.5 mg/dl) or hepatic disease (> 3 X elevations in AST and ALT). - Ophthalmologic conditions associated with a neo-vascular response. - Alcohol or drug abuse, or any other disease process that, in the opinion of the PI, will interfere with the ability of the patient to participate in the study.

Additional Information

Official title Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study
Principal investigator Arshed Quyyumi, MD
Trial information was received from ClinicalTrials.gov and was last updated in November 2013.
Information provided to ClinicalTrials.gov by Emory University.